We are sharing the following press release from Acceleron Pharma, Inc., regarding the progress of their Phase 2 clinical trial of ACE-083. The FSH Society collaborates with Acceleron to help… Read More »
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
Video: Molecular therapy for FSH muscular dytrophy
In this FSH Society webinar, Scott Q. Harper, PhD, of Nationwide Children’s Research Institute describes FSHD genetics and explains how gene and molecular therapy could be used to block the… Read More »
Recent FSHD research publications
Notable findings and advances from the past six months by DANIEL PAUL PEREZ Chief Science Officer, FSH Society Asterisk denotes FSH Society funding acknowledged in paper. “Conservation and innovation in… Read More »
Placing a BET on blocking DUX4
by FRAN SVERDRUP, PHD St. Louis, Missouri DUX4 is considered to be a key cause of muscle degeneration in FSH muscular dystrophy. This is why we are interested in finding… Read More »
Nearly $1.2 million committed in 2017 to FSH muscular dystrophy research
The FSH Society has awarded grants totaling $616,467 to seven research projects submitted during the February 2017 grant cycle. This brings the Society’s total new research commitments to $1,167,260 for… Read More »